Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of telisotuzumab adizutecan combined with RC148 as first-line treatment for non-squamous non-small cell lung cancer
CTR20263784Phase 2Active
- Sponsor
- RemeGen
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab adizutecan, RC148 in Non-small cell lung cancer (NS-NSCLC), sponsored by RemeGen. Started Oct 2026; status: active.
02
Drugs
telisotuzumab adizutecanRC148
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20263784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263784.